Table 3.

Deaths reported in studies on SABR for central lung tumors only.

Reference	Dose prescribed	Immediately adjacent organs	Dose to critical organs	Cause of death/time of death
Haasbeek et al. (30)	60 Gy/8 frx	Pericardium overlapping the target volume R hilum	Unknown	Cardiac event 2.5 years after SABR Respiratory failure
Rowe et al. (32)	50 Gy/4 frx to a metastasis from melanoma	L mainstem bronchus	Airway point dose: 54.2 Gy Airway5cc dose: 12.7 Gy (overall: 14.7 Gy)	Hemorrhage with bronchial necrosis in the region of the maximum point dose 10.5 months after SABR
Oshiro et al. (33)	25 Gy/1 frxa	Hilum of unknown side	Unknown	Hemoptysis 18 months after SABR
Unger et al. (34)	30–40 Gy/5 frx to an endobronchial lesion from mesothelioma	Unknown mainstem bronchus	Maximum point dose: 49 Gy	Bronchial fistula related, 7 months after SABR
Milano et al. (35)	49.5 Gy/11 frx to one central NSCLC followed by 48 Gy/4 frx 15 months later	Bronchus	Bronchus received 98 Gy cumulatively	Hemoptysis 6.5 months after second course of SABR
	50 Gy/10 frx to one central and one peripheral NSCLC followed by 50 Gy/10 frx to three new central lesions and one bulky recurrence of the previously treated peripheral lesion 11 months later	Bronchus and trachea	Unknown	Dyspnea 2 weeks after second course of SABR
	35–50 Gy/10 frx to five central NSCLC	Bronchus and trachea	Unknown	Bronchitis 6 months after second course of SABR
	35 Gy/14 frx then 18 Gy/6 frx to three central NSCLC and 50 Gy/10 frx to one peripheral NSCLC	Bronchus (0.5 cm from tumor) and trachea (1 cm from tumor)	Unknown	Dyspnea 4 months after SABR

^aAfter previous intra-tracheobronchial brachytherapy to bilateral hilar lesions and SABR to the apical area of the same lobe.